Lucira Health, Inc.
LHDX · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $34 | $26 | $90 | $61 |
| % Growth | 31.5% | -71.1% | 48% | – |
| Cost of Goods Sold | $134 | $18 | $51 | $48 |
| Gross Profit | -$100 | $8 | $40 | $13 |
| % Margin | -289.5% | 30.6% | 44.1% | 20.7% |
| R&D Expenses | $9 | $11 | $12 | $9 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $18 | $19 | $14 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $27 | $29 | $26 | $20 |
| Operating Income | -$126 | -$21 | $14 | -$8 |
| % Margin | -367.2% | -81.8% | 15.3% | -12.8% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | $0 |
| Pre-Tax Income | -$127 | -$22 | $13 | -$8 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$127 | -$22 | $13 | -$8 |
| % Margin | -368.9% | -82.9% | 14.5% | -12.3% |
| EPS | -3.15 | -0.54 | 0.31 | -0.19 |
| % Growth | -483.3% | -274.2% | 263.2% | – |
| EPS Diluted | -3.15 | -0.54 | 0.31 | -0.19 |
| Weighted Avg Shares Out | 40 | 40 | 42 | 39 |
| Weighted Avg Shares Out Dil | 40 | 40 | 42 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $2 | $2 | $0 | $1 |
| EBITDA | -$124 | -$19 | $14 | -$7 |
| % Margin | -361% | -74.3% | 15.4% | -10.7% |